What are the differential diagnoses for Evans syndrome, and what is the recommended initial workup and treatment?

Evans Syndrome: Differential Diagnoses, Workup, and Treatment

Evans syndrome is a rare autoimmune disorder defined by the simultaneous or sequential occurrence of immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA), with or without autoimmune neutropenia, and requires aggressive front-line therapy with corticosteroids (with or without IVIG) followed by rituximab as second-line treatment. 1, 2

Definition and Key Diagnostic Features

Evans syndrome represents approximately 5-10% of all warm AIHA cases and 2-5% of all ITP cases in adults, with a high mortality rate and severe clinical course marked by frequent relapses, thrombotic complications, and infections 3. The diagnosis requires:

• Thrombocytopenia (platelet count typically <100 × 10⁹/L)
• Hemolytic anemia with positive direct antiglobulin test (DAT)
• Evidence of immune-mediated destruction (non-cross-reacting autoantibodies against RBCs and platelets)
• Exclusion of other causes

Critical Differential Diagnoses

When evaluating suspected Evans syndrome, you must systematically exclude 1:

Primary Differential Considerations:

• Antiphospholipid syndrome - Check anticardiolipin antibodies, lupus anticoagulant, anti-β2 glycoprotein I
• Systemic lupus erythematosus - ANA, anti-dsDNA, complement levels (C3, C4)
• Lymphoproliferative disorders - CT scan, flow cytometry, bone marrow evaluation
• Common variable immune deficiency - Immunoglobulin levels (IgG, IgA, IgM)
• Drug-induced cytopenias - Detailed medication history
• Infections: HIV, HCV, HBV, CMV, H. pylori, varicella zoster 1, 4

Secondary vs. Primary Classification:

Secondary Evans syndrome accounts for 21-50% of cases 5. Differentiating primary from secondary disease is crucial for prognosis and management 6.

Recommended Initial Workup

The 2024 consensus recommendations provide the most comprehensive diagnostic approach 2:

Essential Laboratory Tests (100% agreement):

• Complete blood count with differential - assess all three cell lines
• Peripheral blood smear - look for spherocytes, schistocytes, anisopoikilocytosis, reduced platelets 7
• Reticulocyte count - assess bone marrow response
• Direct antiglobulin test (DAT) - must be positive for IgG in warm AIHA 7
• Lactate dehydrogenase, indirect bilirubin, haptoglobin - confirm hemolysis

Additional Required Testing:

• Bone marrow evaluation (77% agreement) - shows erythroid hyperplasia, increased immature megakaryocytes, excludes malignancy 2, 7
• Infectious workup: HIV, HCV, HBV, H. pylori testing 4
• Autoimmune panel: ANA, anti-dsDNA, anticardiolipin antibodies, lupus anticoagulant
• Immunoglobulin levels - screen for immunodeficiency
• CT scan - evaluate for lymphadenopathy, organomegaly, thymoma 2

Tests with Lower Agreement (40%):

• Anti-platelet antibodies
• Anti-neutrophil antibodies

Note: Only 40% of experts routinely check anti-platelet and anti-neutrophil antibodies, as these have limited clinical utility 8.

First-Line Treatment Algorithm

The 2024 consensus strongly recommends aggressive front-line therapy with different durations for ITP versus AIHA components 2:

For Immune Thrombocytopenia Component:

Prednisone 1 mg/kg/day (range 0.5-2 mg/kg/day) for 2-4 weeks, then taper over 4-6 weeks 4

Alternative: Dexamethasone 40 mg daily for 4 days 9

For AIHA Component:

Longer corticosteroid duration required compared to isolated ITP - typically 4 weeks before tapering 2

Adjunctive First-Line Therapy:

IVIG 1 g/kg as single dose - use when rapid platelet increase needed or in conjunction with corticosteroids 4

Common Pitfall: Do not use IV anti-D in Evans syndrome patients, as it will exacerbate hemolysis 9. This is contraindicated when autoimmune hemolytic anemia is present.

Second-Line Treatment Recommendations

Rituximab is strongly recommended as second-line therapy 2:

Rituximab Indications (Strong Recommendation):

• First-line for cold-type AIHA
• Second-line for warm-type AIHA
• Second-line for patients with:
  • Antiphospholipid antibodies
  • Previous thrombotic events
  • Associated lymphoproliferative diseases

Rituximab Contraindications:

• Immunodeficiency states
• Severe active infections
• Same contraindications apply to splenectomy 2

Alternative Second-Line Options:

Thrombopoietin receptor agonists (TPO-RAs) - recommended for:

• Chronic ITP component (>12 months)
• Previous grade 4 infection
• Patients who failed corticosteroids/IVIG without splenectomy 1, 2

Splenectomy - traditionally recommended but now discouraged in Evans syndrome due to:

• High infection risk
• Presence of immunodeficiency in many cases
• Availability of effective medical alternatives 2

Third-Line and Refractory Disease

Fostamatinib:

• Recommended as third-line or further-line treatment
• Suggested as second-line for patients with previous thrombotic events 2

Immunosuppressive Agents:

• Moved to third-line or further-line treatment (cyclophosphamide, azathioprine, mycophenolate)
• Consider rituximab plus bendamustine for Evans syndrome secondary to lymphoproliferative disorders 2

Specialized Therapies:

• Recombinant erythropoietin - use in AIHA with inadequate reticulocyte counts 2
• Sutimlimab (complement inhibitor) - for relapsed cold AIHA 2
• Eltrombopag - for refractory cases with severe thrombocytopenia 7

Critical Management Considerations

Transfusion Support:

• Red blood cell transfusions - indicated for symptomatic anemia despite hemolysis risk
• Platelet transfusions - reserve for active bleeding or platelet count <10 × 10⁹/L with bleeding risk 2

Thrombotic Prophylaxis:

Essential consideration given high thrombotic risk in Evans syndrome - assess individual risk factors including antiphospholipid antibodies 2

Antibiotic Prophylaxis:

• Pneumocystis jirovecii prophylaxis during high-dose corticosteroid therapy
• Consider prophylaxis if lymphocyte count <250/μL 4

Monitoring Strategy:

• Weekly CBC monitoring during acute phase
• Close surveillance for infections - viral, bacterial, fungal (especially CMV)
• Screen for underlying conditions - repeat autoimmune and lymphoproliferative workup if initially negative 2, 8

Prognosis and Long-Term Management

Evans syndrome has a severe clinical course with high relapse rates (most patients experience multiple relapses), significant infectious and thrombotic complications, and sometimes fatal outcomes 2. The disease requires long-term multidisciplinary monitoring with attention to:

• Relapse patterns (common and unpredictable)
• Development of additional autoimmune manifestations (83% in pediatric series) 10
• Infectious complications (occur in >80% of patients)
• Thrombotic events
• Evolution to underlying lymphoproliferative or autoimmune disorders

Most clinicians agree that Evans syndrome requires a more aggressive approach than isolated autoimmune cytopenias due to complex pathogenesis, higher relapse risk, and increased thrombotic/infectious complications 8.